Epigenetic silencing of AKAP12 in juvenile myelomonocytic leukemia. Issue 2 (1st February 2016)

• Record Type: Journal Article
• Authors: Wilhelm, Thomas; Lipka, Daniel B.; Witte, Tania; Wierzbinska, Justyna A.; Fluhr, Silvia; Helf, Monika; Mücke, Oliver; Claus, Rainer; Konermann, Carolin; Nöllke, Peter; Niemeyer, Charlotte M.; Flotho, Christian; Plass, Christoph
• Is Part Of: Epigenetics. Volume 11:Issue 2(2016)
• Page Start: 110
• Page End: 119
• Publication Date: 2016-02-01
• Subjects: AKAP12 -- Azacytidine -- DNA methylation -- Epigenetics -- Hematopoiesis -- Juvenile myelomonocytic leukemia -- Leukemia; Epigenesis -- Periodicals; Epigenetica; 572.86505
• DOI: 10.1080/15592294.2016.1145327
• Languages: English
• ISSNs: 1559-2294

Abstract

ABSTRACT: A-kinase anchor protein 12 (AKAP12) is a regulator of protein kinase A and protein kinase C signaling, acting downstream of RAS. Epigenetic silencing of AKAP12 has been demonstrated in different cancer entities and this has been linked to the process of tumorigenesis. Here, we used quantitative high-resolution DNA methylation measurement by MassARRAY to investigate epigenetic regulation of all three AKAP12 promoters (i.e., α, β, and γ) within a large cohort of juvenile myelomonocytic leukemia (JMML) patient samples. The AKAP12 α promoter shows DNA hypermethylation in JMML samples, which is associated with decreased AKAP12 α expression. Promoter methylation of AKAP12 α correlates with older age at diagnosis, elevated levels of fetal hemoglobin and poor prognosis. In silico screening for transcription factor binding motifs around the sites of most pronounced methylation changes in the AKAP12 α promoter revealed highly significant scores for GATA-2/-1 sequence motifs. Both transcription factors are known to be involved in the haematopoietic differentiation process. Methylation of a reporter construct containing this region resulted in strong suppression of AKAP12 promoter activity, suggesting that DNA methylation might be involved in the aberrant silencing of the AKAP12 promoter in JMML. Exposure to DNMT- and HDAC-inhibitors reactivates AKAP12 α expression in vitro, which could potentially be a mechanism underlying clinical treatment responses upon demethylating therapy. Together, these data provide evidence for epigenetic silencing of AKAP12 α in JMML and further emphasize the importance of dysregulated RAS signaling in JMML pathogenesis.